Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year
Status:
Completed
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
This multicenter, prospective, non-interventional study is designed to obtain an accurate
estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under
real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).